Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
330
resultados
Última actualización
16/09/2026 [08:32:00]
Resumen de: US20260265365A1
The present disclosure relates to anti-interleukin-11 (IL-11) antibodies and antigen-binding fragments thereof including their use in the treatment or prevention of an IL-11 (interleukin 11) pathway disease or disorder.
Resumen de: US20260266819A1
The present invention relates to the field of inflammation. More specifically, the present invention provides compositions and methods for treating cerebral inflammation and associated sequelae thereof including cerebral vasospasm. In one embodiment, a method for treating cerebral vasospasm in a patient comprises the step of administering to the patient a PD-1 agonist, wherein a blood sample obtained from the patient comprises elevated PD-1 expression on monocytes relative to a control.
Resumen de: US20260269021A1
A modular breath analysis system is disclosed for analyzing volatile organic compounds in exhaled breath and correlating measured compound profiles with physiological or pathological states of a subject. The system may include a breath sampling subsystem, a breath conditioning subsystem, a sensor array, and a processing subsystem configured to generate a volatile organic compound profile and apply a correlation model. In some embodiments, a base instrument is configured to receive interchangeable sensing modules through mechanical, fluidic, and electrical interfaces. The sensing modules may include gas sensors, flow-routing structures, filters, membranes, identifiers, calibration data, or combinations thereof. Different sensing modules may be configured for different volatile organic compound panels associated with metabolic conditions, blood glucose estimation, respiratory conditions, infectious diseases, cancer, or other physiological or pathological states.
Resumen de: US20260263440A1
0000 Described are processes for the production of a composition comprising (2R, 3R, 4R, 5S)-3, 4, 5-trihydroxypiperidine-2-carboxylic acid (idoBR1), said process comprising the steps of: a) providing plant material from a botanical source comprising plant of the family Cucurbitaceae; b) fractionating said plant material to produce an extract enriched in idoBR1 c) assaying said extract for: i) inhibitory activity against sialidase or TNF-alpha or ii) IL-10 stimulatory activity; and d) formulating said assayed extract with a cosmetically-, nutraceutically- or pharmaceutically-acceptable excipient or carrier to produce a cosmetic, nutraceutical or pharmaceutical composition.
Resumen de: US20260266811A1
The present invention relates to a method for detecting an analyte in a sample suitable for detecting the analyte over a range of concentrations, the method comprising steps (i)-(v). Thus, the present invention provides a method for detecting an analyte in a sample in which only the reporter reagents in the vicinity of the surface of the substrate results in a signal, the signal being a local region of the optical component in the second optical state. It is the set of local regions of the optical component in the second optical state that are detected.
Resumen de: US20260266825A1
0000 Described herein is a method of immunoassay (the “PRO-C17 assay”) for measuring the levels of type XVII collagen ectodomain present in a patient sample, which method of immunoassay can be used for detecting and/or monitoring cancer and/or assessing the severity thereof in a patient. Also described are monoclonal antibodies and assay kits suitable for use in carrying out said methods.
Resumen de: US20260266810A1
The present invention provides a method for detecting two or more analytes in a sample, the method comprising steps (i)-(v). Thus, the present invention provides a method for detecting two or more analytes in a sample in which only the reporter reagents in the vicinity of the surface of the substrate results in a signal, the signal being a local region of the optical component in the second optical state. It is the set of local regions of the optical component in the second optical state that are detected.
Resumen de: US20260264076A1
0000 A multiplexed capillary-flow immunoassay device configured for the simultaneous detection of multiple analytes, specifically, a testing assembly including a detection area, a fluid inlet, and a microfluidic network including at least two microfluidic pathways directed to distinct detection areas each configured to detect a different analyte.
Resumen de: US20260266808A1
The present invention is directed to assay methods and compounds and kits used in such assays.
Resumen de: AU2026204971A1
The present disclosure generally relates to a cell culturing system, and specifically to a three-dimensional cell culturing system for neuronal cells that promotes both structural and functional characteristics that mimic those of in vivo peripheral fibers, including cell myelination. Using a dual hydrogel construct and spheroids comprising neuronal cells, the present disclosure provides methods, devices, and systems for in vitro spatially-controlled, three-dimensional models that permit intra- and extra-cellular electrophysiological measurements and recordings. The three-dimensional hydrogel constructs allow for flexibility in incorporated cell types, geometric fabrication, and electrical manipulation, providing viable systems for culture, perturbation, and testing of biomimetic neural growth with physiologically-relevant results. BSTRACT
Resumen de: US20260266850A1
0000 Methods, compositions and kits useful in the detection, assessment, diagnosis, prognosis and/or treatment of neurological injury or disease or brain injury, such as traumatic brain injury (TBI), are provided in which certain newly discovered protein biomarkers are detected in a biological sample of a subject undergoing testing or evaluation. The methods allow for detection of changes in levels, amounts, or concentrations of the protein biomarkers in a subject compared with those of controls. Detection of the protein biomarkers, and/or levels thereof, provides an indication of biological and biochemical events, e.g., at a cellular level, that are occurring in the subject who is undergoing testing or analysis for the neurological injury or brain injury.
Resumen de: US20260266848A1
0000 Disclosed herein are compositions, kits, and methods for identifying protein, miRNA, or metabolite biomarkers for dystonia, for treating a subject having a dystonia, for selecting a subject for a clinical trial, for selecting a therapeutic agent, for treatment of dystonia in a subject, for classifying a subject having dystonia, and for predicting responsiveness to a dystonia treatment.
Resumen de: US20260266800A1
Systems, devices, and methods herein may include a system for monitoring bodily fluid from a patient. In some embodiments, the system may be configured to collect bodily fluid samples from a patient periodically over time to determine a baseline bodily fluid composition. In some embodiments, the system may use spectrophotometry to determine the baseline bodily fluid composition for the patient. The system may be configured to compare a bodily fluid sample to the baseline bodily fluid composition to detect detecting changes in one or more characteristics of the bodily fluid sample (e.g., composition, absorption spectrum, etc.) from the baseline. Changes in the bodily fluid sample characteristics may be used to predict and/or detect abnormalities or infection for individualized diagnosis.
Resumen de: AU2025223493A1
The present disclosure provides nucleic acids, compositions, and methods of preventing or treating neurodegenerative disease in a subject comprising administering to the subject an agent that targets CHMP2B. In some embodiments the present disclosure provides a method of preventing or decreasing nuclear accumulation of CHMP7 in a cell comprising contacting the cell with an agent that targets expression of CHMP2B in the cell.
Resumen de: US20260265806A1
Embodiments of the instant disclosure relate to early diagnosis and intervention and/or treatment of neurodegenerative disorders and/or brain damage due to normal aging. Certain embodiments disclosed herein relate to quantifying concentrations of ubiquitin c-terminal hydrolase L1 (UCH-L1) in samples obtained from a subject to assess neuronal cell health and/or diagnose the subject with age-related neuronal cell damage. In some embodiments, a subject can be treated with an effective amount of a therapeutic to stabilize and/or reduce concentrations of UCH-L1 in the subject and treat the subject. In other embodiment, a targeted therapeutic agent, process, or task can be assessed for efficacy of reversing brain aging in a subject.
Resumen de: US20260265838A1
0000 Methods of deconvolving a feature profile of a physical system are provided herein. The present method may include: optimizing a regression between a) a feature profile of a first plurality of distinct components and b) a reference matrix of feature signatures for a second plurality of distinct components, wherein the feature profile is modeled as a linear combination of the reference matrix, and wherein the optimizing includes solving a set of regression coefficients of the regression, wherein the solution minimizes 1) a linear loss function and 2) an L2-norm penalty function; and estimating the fractional representation of one or more distinct components among the second plurality of distinct components present in the sample based on the set of regression coefficients. Systems and computer readable media for performing the subject methods are also provided.
Resumen de: US20260265411A1
0000 Isolated histidyl-tRNA synthetase splice variant polynucleotides and polypeptides having non-canonical biological activities are provided, as well as compositions and methods related thereto.
Resumen de: US20260266834A1
0000 A method for detecting proteins and/or their proteoforms is provided herein that includes adding one or more small molecule and one or more protein-binding agent to a biological sample, where a protein corona is formed on the surface of the protein-binding agent, and the proteins and/or their proteoforms in the protein corona are detected by an antibody-based technique or a proteomics technique. Also provided herein is a method for detecting one or more biomarker or a pattern of one or more biomarker associated with a disease or health spectrum condition, as well as a method of diagnosing or predicting a disease in a subject. Compositions including one or more small molecule, one or more protein-binding agent, and one or more biological sample are also provided.
Resumen de: US20260265825A1
0000 A signature for identifying a subject at risk of developing a severe reaction to a SARS-CoV virus by detecting one or more of elevated serum cytokines, reduced monocyte subclasses, differentially expressed genes in monocyte subclasses, differentially expressed gene in CD8+ effector memory T cells, and elevated chromatin accessibility in intermediate monocytes are disclosed herein. Also disclosed are methods for obtaining the signature, methods of identifying a subject at risk of developing a severe reaction to a SARS-CoV virus, and methods of treating COVID-19.
Resumen de: US20260265322A1
0000 Disclosed herein include polynucleotides, expression vectors and compositions enabling expression of a self-assembling proteopathic fusion protein comprising a self-assembling domain fused to a proteopathic polypeptide associated with a proteinopathy. The self-assembling proteopathic fusion protein is capable of forming intracellular protein aggregates that enable robust recapitulation of disease pathology. Provided herein also include methods of using the self-assembling systems disclosed herein to induce proteinopathies (e.g., neurodegenerative diseases) and to screen therapeutic compounds for the treatment of proteinopathies.
Resumen de: WO2026188004A1
Provided are methods for determining the risk or monitoring the progression of Alzheimer's disease in a subject using expression levels of one or more circRNAs. Also provided are methods for treating a subject identified as having or at risk for Alzheimer's disease.
Resumen de: WO2026187110A1
The present invention relates to a method for customized diagnosis of patients with acyl coenzyme A overproduction and screening for therapeutic agents for acyl coenzyme A overproduction-associated diseases by using a metabolite having a nucleophilic amine group. The present invention provides a method capable of indirectly identifying the degree of acyl coenzyme A overproduction by measuring an acyl-product generated upon ingestion of a metabolite having a nucleophilic amine group, and thus enables customized diagnosis of patients with acyl coenzyme A overproduction and screening for customized therapeutic agents for diseases caused by acyl coenzyme A overproduction.
Nº publicación: WO2026187868A1 10/09/2026
Solicitante:
AETON THERAPEUTICS INC [US]
AETON THERAPEUTICS, INC.
Resumen de: WO2026187868A1
The present disclosure provides specific anti-ac-tauK174, anti-ac-tauK274, and ac-tauK353 antibodies, or antigen-binding fragments thereof, and methods of their use in diagnosing, differentiating, targeting, staging, prognosing, and/or treating Alzheimer's Disease and related tauopathies, including traumatic brain injury. Methods of identifying a subject having early Alzheimer's Disease and related tauopathies are also provided, the methods comprising detecting proteins using at least one anti-ac-tauK174 antibody, at least one anti-ac-tauK274 antibody, and/or at least one anti-ac-tauK353 antibody. In some embodiments, the subject is ApoE4-positive.
BOPI
Sede Electrónica
